Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Jaffer A. Ajani et al.|Nature Medicine|2023Cited by 541
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivoJianling Zou, Lin Shen|Cell Death and Disease|2018Cited by 53